Abstract
Dermatomyositis is an autoimmune skin disease with limited treatment options, and lenabasum is a cannabinoid type 2 receptor agonist with anti-inflammatory properties. Our previous work showed that IFNg and IL31 are increased in DM skin vs. skin from healthy controls and lenabasum reduces type 1 interferon (IFN-1) and IL-31 production by DM PBMCs in vitro. Lenabasum 20 mg BID treatment improved CDASI activity (CDASI-A) scores vs. placebo at 1 year in an international, double-blind, randomized Phase 3 trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
